RT Journal Article
SR Electronic
T1 Epidemic Situation and Forecasting if COVID-19 in Saudi Arabia using SIR model
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.05.20091520
DO 10.1101/2020.05.05.20091520
A1 Khoj, Haitham
A1 Mujallad, Alaa F
YR 2020
UL http://medrxiv.org/content/early/2020/05/09/2020.05.05.20091520.abstract
AB Background Saudi Arabia is one of the countries affected by COVID-19 pandemic. This will lead to negative impacts in many sectors. Saudi Arabia not only plays an important role on the economical side because it is the leading country in oil production, but also because it is considered the heart of the Islamic countries. Although protective measures have been implemented in Saudi Arabia, the number of COVID-19 cases has increased.Aims of the study This study aimed to employ SIR model to forecast the peak of COVID-19 progression and an estimation of it is end in Saudi Arabia.Method Based on the World Health Organization data on COVID-19 progression in Saudi Arabia from March 3rd to April 29th, 2020, we reliably estimate the constant parameters and make predictions on the inflection point and potential ending time. Susceptible, Infected, and Recovered are the main components of the SIR model that were used to run the analysis.Result The data showed an interesting result about the peak of the disease progression. It is projected to occur around the 20th day after running the model. According to the model, the peak time will be around the 20th of May. Then the cases will decrease until the 55th day, which is around June 20th.Conclusion The result predicts a second peak and an estimation end of COVID-19 in Saudi Arabia. This data can inform the policy makers, who should try to contain the virus, to be prepared for what is coming next.Key Messages:Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWorld Health Organization